Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 1.97 USD -9.63% Market Closed
Market Cap: 164.9m USD

ROCE
Return on Capital Employed

-73.4%
Current
-47%
Average
-27.2%
Industry

ROCE, or Return on Capital Employed, is a financial ratio that measures a company’s profitability in relation to the capital it employs.

ROCE
-73.4%
=
EBIT
-207.2m
/
Capital Employed
282.2m

ROCE Across Competitors

Editas Medicine Inc
Glance View

Market Cap
164.9m USD
Industry
Biotechnology

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.

EDIT Intrinsic Value
2.64 USD
Undervaluation 25%
Intrinsic Value
Price
What is Return on Capital Employed?

ROCE, or Return on Capital Employed, is a financial ratio that measures a company’s profitability in relation to the capital it employs.

ROCE
-73.4%
=
EBIT
-207.2m
/
Capital Employed
282.2m
What is the ROCE of Editas Medicine Inc?

Based on Editas Medicine Inc's most recent financial statements, the company has ROCE of -73.4%.

Back to Top